Therefore, on November 22, 2013, FDA approved the use of sorafenib for the treatment of advanced and metastatic DTC. Table 1. Clinical trial results of medicine approved by the FDA for the treatment of RAIR-DTC. DrugTime of FDA approvalTargetsstudyphaseTotal numberof patients(drug, placebo)...
Elevar Therapeutics previously sought FDA approval for rivoceranib plus camrelizumab for the frontline treatment of patients with unresectable HCC; however, in May 2024, the FDA issued a complete response letter citing deficiencies in good manufacturing practice at the Hengru...
In July 2023,the FDA accepted for review a new drug application (NDA)seeking the approval of rivoceranib in combination with camrelizumab as a first-line treatment option for patients with unresectable HCC, based on prior data from CARES-310.2However, in May 2024, the regulatory agen...